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Background: Functional heterologous expression of naturally-expressed and apparently functional mammalian
α6*-nicotinic acetylcholine receptors (nAChRs; where ‘*’ indicates presence of additional subunits) has been difficult.
Here we wanted to investigate the role of N-terminal domain (NTD) residues of human (h) nAChR α6 subunit in the
functional expression of hα6*-nAChRs. To this end, instead of adopting random mutagenesis as a tool, we used
15 NTD rare variations (i.e., Ser43Pro, Asn46Lys, Asp57Asn, Arg87Cys, Asp92Glu, Arg96His, Glu101Lys, Ala112Val,
Ser156Arg, Asn171Lys, Ala184Asp, Asp199Tyr, Asn203Thr, Ile226Thr and Ser233Cys) in nAChR hα6 subunit to
probe for their effect on the functional expression of hα6*-nAChRs.
Results: N-terminal α-helix (Asp57); complementary face/inner β-fold (Arg87 or Asp92) and principal face/outer β-fold
(Ser156 or Asn171) residues in the hα6 subunit are crucial for functional expression of the hα6*-nAChRs as variations
in these residues reduce or abrogate the function of hα6hβ2*-, hα6hβ4- and hα6hβ4hβ3-nAChRs. While variations
at residues Ser43 or Asn46 (both in N-terminal α-helix) in hα6 subunit reduce hα6hβ2*-nAChRs function those at
residues Arg96 (β2-β3 loop), Asp199 (loop F) or Ser233 (β10-strand) increase hα6hβ2*-nAChR function. Similarly
substitution of NTD α-helix (Asn46), loop F (Asp199), loop A (Ala112), loop B (Ala184), or loop C (Ile226) residues in hα6
subunit increase the function of hα6hβ4-nAChRs. All other variations in hα6 subunit do not affect the function of
hα6hβ2*- and hα6hβ4*-nAChRs. Incorporation of nAChR hβ3 subunits always increase the function of wild-type or
variant hα6hβ4-nAChRs except for those of hα6(D57N, S156R, R87C or N171K)hβ4-nAChRs. It appears Asp57Lys,
Ser156Arg or Asn171Lys variations in hα6 subunit drive the hα6hβ4hβ3-nAChRs into a nonfunctional state as at
spontaneously open hα6(D57N, S156R or N171K)hβ4hβ3V9’S-nAChRs (V9’S; transmembrane II 9’ valine-to-serine
mutation) agonists act as antagonists. Agonist sensitivity of hα6hβ4- and/or hα6hβ4hβ3-nAChRs is nominally
increased due to Arg96His, Ala184Asp, Asp199Tyr or Ser233Cys variation in hα6 subunit.
Conclusions: Hence investigating functional consequences of natural variations in nAChR hα6 subunit we have
discovered additional bases for cell surface functional expression of various subtypes of hα6*-nAChRs. Variations
(Asp57Asn, Arg87Cys, Asp92Glu, Ser156Arg or Asn171Lys) in hα6 subunit that compromise hα6*-nAChR function
are expected to contribute to individual differences in responses to smoked nicotine.
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Mammalian neuronal nicotinic acetylcholine receptors
(nAChRs) are formed out of six α subunits (α2-α7) and
three β subunits (β2-β4) [1] where in five subunits either
α (e.g., α7, α9α10; etc.) or α plus β come together (e.g.,
α4β2, α4β2α5, α6β2, α6β2β3, α6β4, α7β2; etc.) to form a
ligand gated ion channel [1]. Each nAChR subunit has a
large extracellular N-terminal domain (E1 or NTD),
followed by four transmembrane domains (TM I, II, III
and IV) and a small C-terminal domain (CTD). TM
domains are connected to each other via loops: a small
intracellular loop (C1) connects TM I to TM II, an
extracellular loop (E2) connects TM II to TM III and a
large intracellular loop (C2) connects TM III to TM IV.
The NTD of a human nAChR subunit is presumed to
contain an inner β-sheet (composed of strands β1-β3,Figure 1 Localizations of N-terminal variations to primary/secondary
variant residues in nAChR hα6 subunit in relation to other human nAChR α
using ClustalW. Indicated residues in nAChR hα6 subunits undergoing varia
weakly (Asp57, Asp199 and Asn203) conserved in human nAChR α subunits.
loop regions: Ala112Val (loop A), Ala184Asp (loop B), Ile226Thr (loop C), Asp
Asn171Lys (cysteine-loop). (B) Degree of conservation of variant residues in
organisms: nAChR α6 protein sequences extracted from (GenBank) NP_067
NP_476532.1 (Rat), NP_001029266.1 (Chimpanzee), XP_001099152.1 (Monke
using ClustalW. For both (A) and (B); numbering begins at translation start
interest. However, only segments of the alignment are presented to identif
and numbers above them) and their corresponding variations (noted abov
strongly (:) or weakly (.) conserved residues: hα6 subunit AA residues at po
human nAChR α subunits and nAChR α6 subunits of other organisms. Also
loop E residue N143 that alone or in combination Met145 influences the fuβ5, β6 and β8) and outer β-sheet (composed of strands
β4, β7, β9 and β10) like those typically seen in the crystal
structure of Torpedo muscle nAChR or other eukaryotic
and prokaryotic ACh binding protein subunits [2-5]. The
β-strands connect to each other via loops: they are known
as loops A, B and C in the principal or positive (+) face
and loops D, E and F in the complementary or negative
(−) face (Figures 1 and 2). These loops and additional resi-
dues in the NTD of participating α and β subunits form
the ligand-binding site for nAChRs. The β6-β7 loop has a
pair of disulfide-bonded cysteines separated by 13 residues
that form the cysteine-loop (i.e., cys-loop) motif and it is
essential for nAChR assembly and channel gating [6,7].
Mammalian α6*-nAChRs (where ‘*’ indicates presence
of additional subunits) naturally exist as combinations of
α6 with β2 or β4 alone or with addition of β3 subunitsstructure of nAChR hα6 subunits. (A) Degree of conservation of
subunits: Human nAChR α subunits (α1-α7, α9 and α10) are aligned
tion are fully (Asp92 and Ser156), strongly (Arg87 and Asn171) and
Some of the variations in nAChR hα6 subunit are localized to indicated
92Glu (loop D), Asp199Tyr (loop F) and Asn203Thr (loop F) and
nAChR hα6 subunit in relation to nAChR α6 subunits from other
344.2 (Mouse), NP_004189.1 (Human), NP_990695.1 (Chicken),
y), XP_584902.3 (Cow) and NP_001036149.1 (Zebrafish) are aligned by
methionine of nAChR hα6 subunit and is shown in the regions of
y WT nAChR hα6 subunit AA residues (shaded, upward arrow mark
e the numberings). Symbols below sequences indicate fully (*),
sitions 87 (Arg), 92 (Asp), 156 (Ser) and 171 (Asn) are conserved in both
shown (shaded) are the nAChR hα6 subunit residues including the
nction of hα6*-nAChRs [26].
Figure 2 Localizations of AA variations to secondary structures and interfaces of nAChR hα6 subunit. [(A) and (B)] AA residues
undergoing variation are identified in a 3D model of the nAChR hα6 subunit: A 3D homology model of the nAChR hα6 subunit was generated
based on the crystal structure of Torpedo muscle nAChR α subunit (PDB code: 2BG9:A). Hence structural features are approximate and may
deviate from what seen with α subunit of Torpedo muscle nAChR. β strands constitute inner β-sheet (strand β1-β3, β5, β6 and β8) and outer
β-sheet (strand β4, β7, β9 and β10); and are connect to each other via loops. These loops constitute positive (+) (loops A, B and C) and negative
face (loops D, E and F) of α6 subunit and contribute to subunit assembly, ligand binding, and formation of ligand binding pocket and/or coupling
agonist binding to channel gating. Cysteine loop and other loop residues undergone variations are also identified. [(C)-(E)] Interfaces contributed
by α6 subunit to formation of α6*-nAChR: Adhering to the canonical rule of pentamer formation, α6β2-nAChR would be formed out of three α6
and two β2 subunits [i.e., (i) (α6)3(β2)2-nAChR] or two α6 and three β2 subunits [i.e., (ii) (α6)2(β2)3-nAChR]. In the event β3 or gain-of-function β3
(i.e., β3V9’S) subunits to be integrated into α6β2*-nAChR complexes these subunits would take the position of 3rd α6 subunit in the 1st (i)
configuration or 3rd β2 subunit in the 2nd (ii) configuration [i.e., (iii) (α6)2(β2)2(β3or β3V9’S)-nAChR]. Similarly, β4 subunit would substitute β2
subunit for formation human α6β4-[i.e., (α6)3(β4)2 and (α6)2(β4)3]-nAChR. For formation of (α6)2(β4)2β3- or (α6)2(β4)2β3V9’S-nAChR β3 or β3V9’S subunits
would substitute one α6 subunit in (α6)3(β4)2 configuration or one β4 subunit in (α6)2(β4)3 configuration. Two presumed agonist (ACh or nicotine and
others) binding sites in the interface of α6(+) and β2(−) subunits are identified as ovals. Variations in the structural loops in the (−)-ve face (loop D, E and F)
and (+)-ve face (loop A, B and C) of the hα6 subunit are expected to affect the function of hα6*-nAChRs involving interfaces identified by arrow marks.
Dash and Li Molecular Brain 2014, 7:35 Page 3 of 18
http://www.molecularbrain.com/content/7/1/35[8-17]. α6β2*-nAChRs are proven to be physiologically
important: they play a role in the modulation of dopa-
mine release, reward and reinforcement behavior, and
psychiatric diseases such as schizophrenia, Parkinson’s
disease; etc. [11-13,15,18-21]. The functional role of α6β4*-
nAChRs is poorly understood. Therefore in vitro functional
expression and characterization of these nAChRs are
highly desirable for development of α6*-nAChR spe-
cific ligands to treat diseases associated with themincluding ND [22-24]. However, functional heterol-
ogous expression of mouse or human (h) α6*-nAChRs
has been difficult. There is not emergence of func-
tional α6β2*-nAChRs although poorly functioning
α6β4*-nAChRs could be obtained in some heterologous
expression systems [25-31]. In recent years improved suc-
cess in functional expression of α6*-nAChRs are achieved
by employing mutant and/or chimeric nAChR subunits
[25-28,32-34].
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α6*-nAChR trafficking to the cell membrane [35]. How-
ever, others indicate that coexpression of wild-type (WT)
nAChR β3 subunits has a dominant-negative effect on
function of α6*-nAChRs [25,26,28]. The dominant nega-
tive effect of nAChR β3 subunits could be overcome
by coexpression with mutant β3V9’S subunits [i.e., val-
ine(V)-to-serine(S) mutation at 9’ position in the putative
second transmembrane domain] [25,26]. Upon further
investigation it has been shown that amino acid (AA)
residues in the NTD of α6 subunits influence the effects
of the WT or mutant β3 subunits (i.e., β3V9’S) and are
involved in gain-of-function effects of mutant β3V9’S sub-
units on α6*-nAChR function [26]. These findings also
suggest that co-assembly of nAChR β3 subunits with α6
plus β2 or β4 subunits to form functional nAChR is deter-
mined to some degree by the α6 subunit N-terminal,
extracellular region. This is because improved success in
functional expression of α6*-nAChRs is obtained when
chimeric mouse-human α6 subunits (where the N-
terminal domain of mouse α6 subunit is fused to the rest
of human α6 subunits) are employed instead of WT hα6
subunit. This has led to the discovery of Asn143 in the
putative loop E region of the NTD of hα6 subunit as a key
determinant for the heterologous functional expression of
α6*-nAChRs [26-28].
Therefore it appears that there probably exist additional
residues in the NTD of hα6 subunit some of which will be
of crucial importance and mutations in them will not be
tolerated, and others which could be target for improved
functional expression of α6*-nAChRs. In the absence of
these information (and not to use random mutagenesis as
a tool towards this end) we reasoned to use naturally
occurring rare variations in the NTD of hα6 subunit as
probes to uncover N-terminal molecular bases important
for functional expression of hα6hβ2*- and hα6hβ4*-
nAChRs. To this end we evaluated the effect of 15 natur-
ally occurring rare missense mutations, that occur in
various regions of the N-terminal extracellular domain
of hα6 subunit [N-terminal α-helix: Ser43Pro, Asn46Lys
and Asp57Asn; complementary face/inner β-fold: Arg87Cys
(β2-strand); Asp92Glu, Arg96His and Glu101Lys (loop D/
β2-β3 loop); Ser156Arg (β6-strand); and Asp199Tyr and
Asn203Thr (loop F)] and principal face/outer β-fold:
Ala112Val (loop A), Asn171Lys (cysteine loop, potential
site for N-glycosylation), Ala184Asp (loop B), Ile226Thr
(loop C) and Ser233Cys (β10-strand); see Figures 1 and 2;
Table 1], on the functional expression of hα6*-nAChRs.
On occasion we took aid of gain-of-function hβ3 subunits
(i.e., hβ3V9’S = hβ3V273S) (to increase receptor sensitivity)
and a codon optimized nAChR hβ2 subunit (to increase
receptor expression efficiency) to provide additional insight
into the effect of these natural variations on the functional
expression of hα6*-nAChRs. Our results indicate thatsome of the rare variations abrogate, decrease, increase or
do not affect the functional expression of hα6hβ2*- and
hα6hβ4*-nAChRs. There also appear to be a subtype spe-
cific effect of some of these variations. By undertaking this
study, as anticipated, we were able to uncover some of the
N-terminal molecular bases in hα6 subunit that could be
taken advantage for modulating functional expression of
hα6hβ2*-, hα6hβ4- and hα6hβ4hβ3-nAChRs. These results
provide foundations for undertaking more specialized and
individual mutation specific studies later on.
Results
Bioinformatic analyses indicate possible functional
consequences of rare variations in nAChR α6 subunits
Information retrieved from NCBI dbSNP database, NHLBI
Grand Opportunity Exome Sequencing Project (ESP),
multiple protein sequence alignment of human nAChR α
subunits, multiple protein sequence alignment of nAChR
α6 subunits from various model organisms and homology
model of nAChR hα6 subunit (Figures 1 and 2) are com-
bined to present an overview of the characteristics of the
15 single nucleotide variations (SNVs) evaluated for their
effect on function of hα6*-nAChRs (Table 1). African
American and European American populations sampled in
the ESP indicate that these nucleotide variations are rare
and their combined frequency ranges from 0.001 to 0.3%
(Table 1).
Full length protein sequence alignments of human
nAChR α subunits indicate that fully conserved (Asp92
and Ser156), strongly conserved (Arg87 and Asn171), weakly
conserved (Asp57, Asp199 and Asn203), and non-conserved
(the rest 8: Ser43, Asn46, Arg96, Glu101, Ala112, Ala184, Ile226
and Ser233) AAs in the NTD of nAChR hα6 subunit have
undergone variations [Figures 1(A)]. Also nAChR hα6
subunit AAs undergoing variation are fully conserved
(Asn46, Asp57, Arg87, Asp92, Glu101, Ser156, Asn171, Ala184,
Ile226 and Ser233), strongly conserved (Ala112 and Asp199),
weakly conserved (Asn203) and non-conserved (the rest 2:
Ser43 and Arg96) in an alignment of nAChR α6 subunits
from various organisms [Figure 1B]. Together, these results
indicate that nAChR hα6 subunit AAs at positions 87 (Arg),
92 (Asp), 156 (Ser), and 171 (Asn) are conserved in both hu-
man nAChR α subunits and nAChR α6 subunits from other
organisms. Lacking a priori knowledge, we hypothesize that
these variations at conserved AAs would have an effect on
the structure and/or function of hα6*-nAChRs.
Positions of the WT or variant AAs in nAChR hα6 sub-
unit are mapped to their secondary structural features such
as α-helices, β-strands and loops (Figures 1 and 2; Table 1)
by sequence alignment and/or comparison to other
nAChR subunits and most prominently to that of the
muscle nAChR α subunits of Torpedo marmorata (PDB
code: 2BG9.A) [2]. We hypothesized that some of these
variations in nAChR hα6 subunit occurring in the loop A
Table 1 Characteristics of single nucleotide variants (SNVs) located in the N-terminal domain of nAChR hα6 subunit
rs ID # Nucleotide position
in chromosome 8








Conservation in α6 subunits
of other species
NTD location
rs140930963 8:42620300 G = 37/A = 10721 S43P No - α-helix
rs80342906 8:42620289 C = 6/G = 10752 N46K No N: yes α-helix
rs149966755 8:42620258 T = 1/C = 10757 D57N ‘-‘ve to zero D: weak D: yes α-helix
unknown 8:42614217 A = 2/G = 10756 R87C ‘+’ve to zero R: strong R: yes Complementary face/inner
β-sheet
Strand β2
rs146332801 8:42612169 C = 1/A = 10755 D92E D: fully D: yes β2-β3 loop (loop D)
rs188620180 8:42612158 A/G R96H No - β2-β3 loop
rs200380236 8:42612144 T = 1/C = 10755 E101K ‘-‘ve to ‘+’ve No E: yes β2-β3 loop/1MIR
unknown 8:42611874 C = 1/A = 10757 S156R neutral to ‘+’ve S: fully S: yes Strand β6
unknown 8:42611747 A = 2/C = 10756 D199Y ‘-’ve to neutral D: weak D: weak β8-β9 loop (loop F)
rs143385261 8:42611734 G = 3/T = 10755 N203T N: weak N: weak β8-β9 loop (loop F)
rs141518931 8:42612110 A = 1/G = 10755 A112V No A: yes Principal face/outer β-sheet β3-β4 loop (Loop A)
rs79945499 8:42611829 G/C N171K neutral to ‘+’ve N: strong N: yes β6-β7 (Cysteine loop)
rs200745568 8:42611791 T = 1/G = 10757 A184D neutral to ‘-‘ve No A: yes β7-β8 loop (loop B)
rs199987912 8:42611665 G = 2/A = 10756 I226T No I: yes β9-β10 loop (loop C)
unknown 8:42611644 C = 1/G = 10757 S233C No S: yes Strand β10
1MIR: Main immunogenic region.
Pertinent information about the N-terminal variations in nAChR hα6 subunit such as their reference SNP (rs) identification (ID) number, location in the chromosome 8, combined frequency of nucleotide variations discovered
in more than 10000 genomes of African Americans (AA) and European Americans (EA) (Exome Sequencing Project: ESP; https://esp.gs.washington.edu/), change in amino acids, change in electrical charges, conservation in the
human nAChR α subunits (Figure 1), conservation in nAChR α6 subunit of other species and putative locations in the secondary structure of the nAChR hα6 subunits (Figure 2) are presented. The WT AAs with the exception of
S43 are strongly conserved in nAChR α6 subunits studied from a limited number of other species (Figure 1). Please note that hα6 variations R87C, S156R, D199Y and S233C retrieved from ESP do not have an rs ID number yet.
The N-terminal domain of a typical human nAChR subunit is presumed to contain an inner β-sheet (strand β1-β3, β5, β6 and β8) and outer β-sheet (strand β4, β7, β9 and β10) like those of seen in the crystal structure of
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loop D/β2-β3 loop (Arg87Cys, Asp92Glu and Arg96His),
loop F (Asp199Tyr and Asn203Thr) and cysteine-loop
(Asn171Lys) would affect the structure and/or function of
hα6*-nAChR as these regions are known to be important
in subunit assembly, ligand binding and/or signal trans-
duction of various other subtypes of nAChRs [2,7]. Also
change in the electrical properties and other characteris-
tics of the AAs as a result of the variation potentially
could impact the intra- and/or inter subunit molecular
interactions involving ionic and other types bonds that
may affect the structure and/or function of hα6*-nAChRs
(Tables 1 and 2).
Current responses are null whether WT nAChR hα6 subunits
are expressed in oocytes with WT or codon optimized hβ2
subunits alone or in the additional presence of hβ3 subunits
Functional expressions of human α6β2- and α6β2β3-
nAChRs were not achieved in Xenopus oocytes whether
WT or codon optimized human nAChR β2 subunits were
expressed with hα6 subunits alone or in the additional
presence of hβ3 subunits.
Human α6β2β3V9’S-nAChRs are functional whether they
are expressed using WT or codon optimized nAChR hβ2
subunits but the current responses are higher from
oocytes expressing the codon optimized hβ2 subunits
Incorporation gain-of-function hβ3V9’S subunits instead
of WT hβ3 subunits lead to expression of functionalTable 2 Primers used to create single nucleotide variation
in nAChR α6 subunit cDNA
















For mutants, the first amino acid (single letter code, numbering begins at the
translation start methionine) designates the WT human nAChR hα6 subunit
residue that is replaced with the indicated, second amino acid. In the forward
primer nucleic acid sequence, capitalization indicates the nucleotide changed
from the WT subunit to create the corresponding mutant.hα6hβ2hβ3V9’S-nAChRs but their peak current responses
are minimal [25]. In an earlier effort [26], this observa-
tion could not be achieved although the use of mouse
(m) α6 subunit instead of hα6 subunit led to expression
of functional mα6hβ2hβ3V9’S-nAChRs [26]. Nonetheless
here we show that functional hα6hβ2hβ3V9’S-nAChRs
could be expressed in oocytes by injecting higher
amount of cRNAs (~23 ng) for each subunit. Fur-
thermore the use of a codon optimized nAChR hβ2
subunit instead of a WT hβ2 subunit increases the
current responses of human α6β2β3V9’S-nAChRs. Results
(Figures 3 and 4) indicate that oocytes co-injected with hα6
subunit, codon optimized hβ2 subunit, and hβ3V9’S
subunit cRNAs elicit ~31-fold higher (15 ± 2 nA vs.
469 ± 75 nA; p < 0.05) current responses than those
injected with hα6, hβ2 and hβ3V9’S subunit cRNAs in
response to activation by 100 μM nicotine. Therefore
we decided to measure current responses from oo-
cytes coexpressing variant-hα6 subunits, codon opti-
mized hβ2 subunits and hβ3V9’S subunits first and then
verify these results using WT hβ2 subunits wherever it is
feasible.
Human α6β4- and α6β4β3-nAChRs are functional and
current responses obtained from oocytes expressing
α6β4β3-nAChRs are higher than those expressing
hα6hβ4-nAChRs
While hα6hβ4- and hα6hβ4hβ3- nAChRs are difficult to
express [25,26], functional hybrid nAChR consisting of
mα6, hβ4 and hβ3 subunits (i.e., mα6hβ4hβ3-nAChR)
[26] and others such as human α2β4-, α3β2-, α3β4-,
α4β2- or α4β4-nAChRs could be easily expressed in
oocytes using a relatively lower amount (~1-4 ng) of
cRNA for each subunit [36]. In this study we used
relatively larger amount of cRNA (~23 ng) for each sub-
unit for functional expression of hα6hβ4- or hα6hβ4hβ3-
nAChRs. This approach has been shown to result in
functional expression of hα6hβ4*-nAChRs [29]. Like
reported previously [29], here we observed hα6hβ4- and
hα6hβ4hβ3-nAChRs are functional and the peak current
responses of hα6hβ4hβ3-nAChRs exceed those of
hα6hβ4-nAChRs (35 ± 2 nA vs. 407 ± 34 nA in response
to 100 μM nicotine, ~12 -fold increase, p < 0.05; and 25 ±
3 nA vs. 502 ± 60 nA in response to 1000 μM ACh, ~20-
fold increase, p < 0.05), demonstrating a potentiation effect
of hβ3 subunits on the peak current responses of hα6hβ4-
nAChRs (Figures 5–6 and 7; Table 3 and Additional file 1:
Figure S1 and Table S1). The EC50 values for nicotine and
ACh acting at hα6hβ4hβ3-nAChR is determined to be
12 μM and 40 μM respectively (Tables 3 and Additional
file 1: S1). Lack of current responses at lower concentra-
tions of nicotine or ACh precluded our ability to construct
CR curves for hα6hβ4-nAChRs.
Figure 3 Variations in nAChR hα6 subunit influence the current responses of human α6β2β3V9’S-nAChRs expressed in oocytes using
codon optimized nAChR hβ2 subunits. Mean (±SEM) peak inward current responses upon exposure to 100 μM nicotine (5 sec exposure;
ordinate) are estimated from oocytes (n = 3-7) voltage clamped at −70 mV and heterologously expressing the indicated nAChR subunits. Current
responses of hα6hβ2hβ3V9’S-nAChR are completely abolished (D57N or S156R), partially abolished (S43P, N46K, R87C, D92E or N171K), not
changed (E101K, A112V, A184D, N203T or I226T) and increased (R96H, D199Y or S233C) as a result of the indicated variations in nAChR hα6
subunits. Oocytes coexpressing nAChR hα6(D199Y) subunits, codon optimized hβ2 subunits and hβ3V9’S subunits yield largest current responses
to nicotine. Comparisons of peak current responses between control (hα6hβ2hβ3V9’S-nAChR) and variant nAChR groups were analyzed using
one-way ANOVA with Dunnett’s multiple comparisons test (*, p < 0.05; and **, p < 0.01).
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responses of human α6β2β3V9’S-nAChRs but they
do not alter the null responses observed from oocytes
coexpressing nAChR hα6 and hβ2 (WT or codon
optimized) subunits in the presence or absence
of hβ3 subunits
We sought to determine whether coexpression of the vari-
ant nAChR hα6 subunits with WT or codon optimized
hβ2 subunits in the presence or absence of hβ3 subunits
would result in expression of functional nAChR in oo-
cytes. We did not observe detectable current responses
from these oocytes except that coexpression of codon
optimized hβ2 and hβ3 subunits with either hα6D199Y or
hα6S233C subunits appeared to result in functional
nAChRs but their peak current responses to 100 μM nico-
tine (in the range of 10 to 20 nA) could not be reliably
and consistently measured (data not shown). However,
oocytes coexpressing nAChR hα6, hα6S43P, hα6N46K,
hα6D92E, hα6R96H, hα6E101K, hα6A112V, hα6A184D, hα6D199Y,
hα6N203T, hα6I226T or hα6S233C subunits with codon opti-
mized hβ2 subunits and gain-of-function hβ3V9’S subunits
responded to the application of 100 μM nicotine with
peak currents (Imax, mean ± SE) of 469 ± 75 nA, 47 ± 9 nA,118 ± 33 nA, 66 ± 20 nA, 1075 ± 175, 551 ± 156 nA, 293 ±
24 nA, 616 ± 95 nA, 2076 ± 68 nA, 762 ± 253 nA, 753 ±
137 nA or 1582 ± 221 nA, respectively (Figure 3). Most of
the oocytes expressing nAChR hα6D57N, hα6R87C, hα6S156R
or hα6N171K subunits along with codon optimized hβ2
subunits and hβ3V9’S subunits yield null responses to nico-
tine although on occasion, upon repeated attempts, some
of these oocytes yield 10–30 nA of current in responses
to 100 μM nicotine. Therefore variations Asp57Asn,
Arg87Cys, Ser156Arg or Asn171Lys abolish; variations
Ser43Pro or Asn46Lys reduce (75-93%; p < 0.05); variations
Asp92Glu, Glu101Lys, Ala112Val, Ala184Asp, Asn203Thr
or Ile226Thr do not affect (p > 0.05); and variations
Arg96His, Asp199Tyr or Ser233Cys increase (p < 0.05; ~2-
5 fold) the peak current responses of hα6hβ2hβ3V9’S-
nAChRs.
We attempted to reproduce these results using WT hβ2
subunits. Oocytes coexpressing nAChR hα6D57N, hα6R87C,
hα6S156R, hα6N171K, hα6S43P, hα6N46K or hα6D92E subunits
along with WT hβ2 subunits and hβ3V9’S subunits did
not yield current responses to nicotine. These results
conversely indicate that a null response observed for
hα6(S43P, N46K or D92E)hβ2hβ3V9’S-nAChRs using WT
Figure 4 Variations in nAChR hα6 subunit influence the current responses of human α6β2β3V9’S-nAChR expressed in oocytes using WT
nAChR hβ2 subunits. Attempts were made to verify the results obtained for human α6β2β3V9’S-nAChR using WT nAChR hβ2 subunits instead
of codon optimized hβ2 subunits. Mean (±SEM) peak inward current responses upon exposure to 100 μM nicotine (5 sec exposure; ordinate) are
estimated from oocytes (n = 3-7) voltage clamped at −70 mV and heterologously expressing the indicated nAChR subunits. (A) Oocytes coexpressing
nAChR hα6(R96H, D199Y or S233C), hβ2WT and hβ3V9’S subunits yield current responses to nicotine that are higher than those expressing nAChR hα6, hβ2WT
and hβ3V9’S subunits. These results are in agreement with those obtained using codon optimized hβ2 subunits. (B) Initial recordings 3 days after cRNA
injection indicated that oocytes expressing WT hα6 or variant hα6(E101K, A112V, A184D, N203T or I226T) subunits along with WT hβ2 and hβ3V9’S subunits
yield ~10-30 nA of current in response to 100 μM nicotine [see the hα6hβ2hβ3V9’S-nAChR response in (A)]. However recordings done after 2
additional days of waiting indicated that nicotine elicited current responses from human α6E101Kβ2β3V9’S-, α6A112Vβ2β3V9’S-, α6A184Dβ2β3V9’S-,
α6N203Tβ2β3V9’S- or α6I226Tβ2β3V9’S-nAChRs are equal (p > 0.05) to those obtained from human α6β2β3V9’S-nAChRs. These results are in agreement
with those obtained using codon optimized hβ2 subunits. Comparisons between groups were analyzed using one-way ANOVA with Tukey’s post hoc
comparison and only those differ from the control (hα6hβ2hβ3V9’S-nAChR) are shown with asterisks. *, p < 0.05; and **, p < 0.01.
Figure 5 Variations in nAChR hα6 subunit influence the current responses of hα6hβ4-nAChRs. Mean (±SE) peak inward current responses
upon exposure to 100 μM nicotine (5 sec exposure; ordinate) are estimated from oocytes (n = 6-9) voltage clamped at −70 mV and heterologously
expressing the indicated nAChR subunits. Oocytes coexpressing hα6A184D (variation in loop D) and hβ4 subunits yield largest current responses to
100 μM nicotine. Comparisons of peak current responses between control (hα6hβ4-nAChR) and variant groups were analyzed using one-way ANOVA
with Dunnett’s multiple comparisons test (*, p < 0.05; and **, p < 0.01).
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Figure 6 Variations in nAChR hα6 subunit influence the current responses of hα6hβ4hβ3-nAChRs. Mean (±SE) peak inward current
responses upon exposure to 100 μM nicotine (5 sec exposure; ordinate) are estimated from oocytes (n = 6-11) voltage clamped at −70 mV and
heterologously expressing the indicated nAChR subunits. Oocytes coexpressing hα6(D57N, R87C, S156R or N171K) subunits plus hβ4 and hβ3 subunits
do not yield current responses to nicotine though those coexpressing hα6, hβ4 and hβ3 subunit yield fairly robust current responses. hα6
subunit variation Asp92Glu (in loop D) partially abolishes the peak current responses of hα6hβ4hβ3-nAChRs. hα6 subunit variations Asn46Lys, Arg96His,
Glu101Lys, Ala112Val, Ala184Asp, Asn203Thr, Ile226Thr or Ser233Cys do not affect nicotine elicited peak current responses of hα6hβ4hβ3-nAChRs.
Comparisons between control (hα6hβ4hβ3) and variant groups were analyzed using one-way ANOVA with Dunnett’s multiple comparisons test
(*, p < 0.05; and **, p < 0.01).
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is detected using the codon optimized hβ2 subunits.
Hence a null function detected using WT hβ2 subunits in
fact is a level of current response that is below our limit of
detection.
This prompted us to evaluate current responses from
oocytes coexpressing nAChR hα6R96H, hα6D199Y or
hα6S223C subunits in conjunction with WT hβ2 and
hβ3V9’S subunits as these three variants expressed in
oocytes in the presence of codon optimized hβ2 and
hβ3V9’S subunits elicit largest responses to nicotine
(Figure 3). Surprisingly, there was emergence of
(hα6R96H, D199Y or S223C)hβ2hβ3V9’S-nAChRs and their
peak current responses to 100 μM nicotine were higher
(p < 0.05; ~2-5 fold) than those of hα6hβ2hβ3V9’S-nAChRs
[Figure 4A].
The (hα6, hα6E101K, hα6A112V, hα6A184D, hα6N203T or
hα6I226T)hβ2hβ3V9’S-nAChRs expressed in oocytes 3 days
after injection yielded ~15-30 nA (data not shown)
current in responses to 100 μM nicotine. In order to con-
firm that these current responses are real and due to the
expression of functional nAChRs, recordings were done
after waiting for additional 2 days. This time peak current
responses could be reliably measured [Figure 4B]. Mean(±SEM) level of current responses for these nAChR
ranged from 53 ± 12 nA (for hα6N203Thβ2hβ3V9’S-nAChR)
to 123 ± 40 nA [for hα6I226Tβ2β3V9’S-nAChR; Figure 4B].
However, they were similar (p > 0.05) to those of the con-
trol. Hence coexpression with WT hβ2 subunits instead of
codon optimized hβ2 subunits did not alter the outcome.
Note that the current responses of hα6hβ2hβ3V9’S-
nAChRs to nicotine were assayed 5 days after injection
(but not 3 days after injection as shown for Figure 4A].
Hence there is disparity in peak current responses of
hα6hβ2hβ3V9’S-nAChR in the two panels of Figure 4.
Variations in nAChR hα6 subunit influence the current
responses of hα6hβ4-nAChRs
Oocytes coexpressing nAChR hα6, hα6S43P, hα6N46K,
hα6D92E, hα6R96H, hα6E101K, hα6A112V, hα6A184D,
hα6D199Y, hα6N203T, hα6I226T or hα6S233C subunits with
hβ4 subunits responded to the application of 100 μM
nicotine with peak currents (Imax, mean ± SE) of 35 ±
2 nA, 39 ± 5 nA, 78 ± 11 nA, 19 ± 2 nA, 73 ± 10 nA, 73 ±
10 nA, 110 ± 22 nA, 122 ± 12 nA, 90 ± 11 nA, 33 ± 3 nA,
81 ± 10 nA or 73 ± 20 nA, respectively (Figure 5). Pre-
dominantly null responses were observed from oo-
cytes coexpressing nAChR hα6D57N, hα6R87C, hα6S156R
Figure 7 Nicotinic agonists act as antagonists at hα6(D57N, S156R or N171K)hβ4hβ3V9’S-nAChRs. (A) Representative traces are shown for inward
or outward current responses from oocytes (voltage clamped at -70 mV) responding to the application of indicated concentrations of nicotine or
atropine (shown with the duration of drug exposure as black bars above or below the traces) and expressing hα6hβ4hβ3V9’S- [(A) (i) and (v)],
hα6D57Nhβ4hβ3V9’S- [(A) (ii) and (vi)], hα6S156Rhβ4hβ3V9’S [(A) (iii) and (vii)] or hα6N171Khβ4hβ3V9’S- [(A) (iv) and (viii)] nAChRs. Calibration bars
are for 200 (i), 40 [(ii), (iii) and (iv)] or 100 [(v), (vi), (vii) and (viii)] nA currents (vertical) or 5 sec (horizontal). Results for these and other studies were
used to estimate mean (±SE) peak outward current responses to 100 μM nicotine (B), 100 μM ACh (C) or 1000 μM atropine (D) from oocytes
(n=3-6) heterologously expressing the indicated nAChR subunits. hα6(D57N, S156R or N171K)hβ4hβ3V9’S-nAChRs elicit outward (positive) current in
response to nicotine (B) or ACh (C) which is completely absent from hα6hβ4hβ3V9’S-nAChRs [(B) and (C)]. hα6(D57N, S156R or N171K)hβ4hβ3V9’S-nAChRs
in rare occasion display minuscule inward currents in response to ACh or nicotine (data not shown). Comparisons between groups were analyzed
using one-way ANOVA with Tukey’s post hoc comparison and only those differ from the control (hα6hβ4hβ3V9’S-nAChR) are marked with asterisks.
***; p < 0.001.
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occasionally some of these oocytes seemed to yield
10–20 nA of current in responses to 100 μM nico-
tine. Hence current responses of hα6hβ4-nAChRs
were increased (p < 0.05; ~2-3-fold) as a result of
Asn46Lys, Ala112Val, Ala184Asp, Asp199Tyr or Ile226Thr
variations and compromised (p < 0.05; ~100%) due to
Asp57Asn, Arg87Cys, Ser156Arg or Asn171Lys variations
in hα6 subunit. Also current responses to 1000 μM ACh
were increased (p < 0.05) from oocytes coexpressing
nAChR hα6A184D or hα6D199Y subunits and hβ4 subunits
relative to those coexpressing hα6 and hβ4 subunits
(Table 3).Variations in nAChR hα6 subunit influence the current
responses of human α6β4β3-nAChRs
Mean (±SE) peak current responses obtained from oo-
cytes expressing nAChR hβ3 and hβ4 subunits in the
presence of nAChR hα6, hα6S43P, hα6N46K, hα6D92E,
hα6R96H, hα6E101K, hα6A112V, hα6A184D, hα6D199Y,
hα6N203T, hα6I226T or hα6S233C subunits were 407 ± 34 nA,
208 ± 22 nA, 307 ± 39 nA, 126 ± 5 nA, 513 ± 42 nA, 467 ±
54 nA, 482 ± 59 nA, 554 ± 108 nA, 276 ± 47 nA, 371 ±
68 nA, 403 ± 79 nA or 536 ± 66 nA, respectively (Figure 6).
Oocytes expressing hα6D57N, hα6R87C, hα6S156R or
hα6N171K subunits in the presence of nAChR hβ4 and
hβ3 subunits did not elicit current responses to nicotine
Table 3 Parameters for ACh action at WT or variant hα6hβ4*- nAChRs
Potency Peak response
nAChR subunit combinations n EC50 (μM) (95% CI) nH ± SE nH n Mean Imax ± SE (nA) Imax conc. (μM)
hα6 + hβ4 181 - 5 30 ± 3 1000
hα6(R96H) + hβ4 3 - - 3 31 ± 4 1000
hα6(A184D) + hβ4 3 11 (9.3-13) 1.3 ± 0.16 5 86 ± 5 ⬆ 1000
hα6(D199Y) + hβ4 3 16 (14–19) 1.1 ± 0.04 5 73 ± 12⬆ 1000
hα6(S233C) + hβ4 3 14 (11–17) 0.95 ± 0.08 4 90 ± 23 1000
hα6 + hβ4 + hβ3 4 40 (29–56) 1.1 ± 0.1 4 502 ± 60▲ 1000
hα6(R96H) + hβ4 + hβ3 3 21 (17–26) ⬇ 0.96 ± 0.07 6 905 ± 146▲ 1000
hα6(A184D) + hβ4 + hβ3 3 17 (14–22) ⬇ ▲ 0.97 ± 0.04 7 788 ± 202▲ 1000
hα6(D199Y) + hβ4 + hβ3 3 24 (20–28) ⬇ ▲ 1.1 ± 0.07 7 494 ± 51▲ 1000
hα6(S233C) + hβ4 + hβ3 3 16 (12–21) ⬇ 0.98 ± 0.1 3 771 ± 150▲ 1000
1From Kuryatov et al. (2000).
Potencies [micromolar EC50 values with 95% confidence intervals (CI)], Hill coefficients (nH ± SE), mean ± SE peak response (Imax in nanoamps) and concentrations
(μM) where maximal peak current amplitudes (Imax) achieved are provided for ACh acting at nAChR composed of the indicated subunits and from the indicated
number of independent experiments (n) based on studies as shown in Figure 8. ⬆ or ⬇ indicate a significant (p < 0.05) increase or decrease in indicated parameter
at the indicated nAChR subtype relative to nAChR containing the same subunits but in the presence of the WT hα6 subunit (i.e., hα6hβ4- vs. variant-hα6hβ4-
nAChR; hα6hβ4hβ3- vs. variant-hα6hβ4hβ3- nAChR). ▲ or ▼ indicate a significant (p < 0.05) increase or decrease, respectively, in indicated parameter at the
indicated nAChR subtype relative to nAChR containing the same subunits but in the absence WT β3 subunits (i.e., hα6hβ4- vs. hα6hβ4hβ3- nAChR;
variant-hα6hβ4- vs. variant-hα6hβ4hβ3- nAChR). ‘-‘ indicates that inconsistent functional responses in two electrode voltage clamp studies precluded
determination of the parameter of interest.
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subunits into (hα6, hα6S43P, hα6N46K, hα6D92E, hα6R96H,
hα6E101K, hα6A112V, hα6A184D, hα6D199Y, hα6N203T,
hα6I226T or hα6S233C)hβ4-nAChR complexes, but not into
putative (hα6D57N, hα6R87C, hα6S156R or hα6N171K)hβ4-
nAChR complexes, resulted in potentiated (3–12 fold;
p < 0.05) current responses from oocytes (see Figures 5
and 6). These former results are consistent with the
observation that incorporation of hβ3 subunits poten-
tiates the peak current responses of hα6hβ4-nAChRs
[29]. Therefore variations Asp57Asn, Arg87Cys,
Ser156Arg or Asn171Lys abolish (p < 0.01); variation
Asp92Glu reduces (p < 0.05); and variations Asn46Lys,
Arg96His, Glu101Lys, Ala112Val, Ala184Asp, Asp199Tyr,
Asn203Thr, Ile226Thr or Ser233Cys do not affect (p > 0.05)
the peak current responses of hα6hβ4hβ3-nAChRs.
Also variations Arg96His, Asp199Tyr, Ala184Asp or
Ser233Cys in hα6 subunit do not affect (p > 0.05) the ACh
(1000 μM) induced current responses of hα6hβ4hβ3-
nAChRs (Table 3).
Further studies on Asp57Asn, Ser156Arg and Asn171Lys
variations reveal that nicotine, ACh or atropine acts as
antagonists at hα6D57Nhβ4hβ3V9’S, hα6S156Rhβ4hβ3V9’S
and hα6N171Khβ4β3V9’S-nAChRs
In order to further understand the bases for the null
effects of Asp57Asn, Arg87Cys, Ser156Arg and Asn171Lys
variations in nAChR hα6 subunit, we coexpressed nAChR
hα6, hα6D57N, hα6R87C, hα6S156R or hα6N171K subunits with
hβ4 and gain-of-function hβ3V9’S subunits and current
responses from these oocytes to nicotine (100 μM), ACh(100 μM) or atropine (1000 μM) were measured. As
expected hα6hβ4hβ3V9’S-nAChRs yielded robust inward
current in response to activation by nicotine or ACh and
outward reversible currents in response to blockade of
spontaneously opening channels by atropine (Figure 8)
[26-28,36]. However, hα6D57Nhβ4hβ3V9’S, hα6S156Rhβ4hβ3V9’S
or hα6N171Khβ4β3V9’S-nAChRs expressed in oocytes pro-
duced outward reversible currents in response to ACh,
nicotine or atropine (Figure 8). Such outward reversible
currents were not observed from oocytes coexpressing
hα6, hα6D57N, hα6S156R or hα6N171K subunits with hβ2
and hβ3V9’S subunits (data not shown). These results indi-
cate that hβ3V9’S (a surrogate for hβ3) subunits in fact
integrates into hα6D57Nhβ4, hα6S156Rhβ4 or hα6N171Khβ4-
nAChR complexes. Apparently these cell surface ex-
pressed and spontaneously opening nAChRs are not
responsive to agonist action of nicotine or ACh but it
seems ACh, nicotine and also atropine are acting as antag-
onists at these nAChRs. Current responses to ACh,
nicotine or atropine were not obtained from oocytes
coexpressing nAChR hβ4 or hβ2 subunits and hα6R87C
and hβ3V9’S subunits (Figure 2).
Variations in nAChR hα6 subunits that affect the agonist
(nicotine or ACh) sensitivity of hα6hβ4*-nAChRs
Concentration-response (CR) curves for WT or variant
hα6hβ4*-nAChR were produced, wherever feasible, in a
manner to glean maximum comparative information
about them. As we could not produce CR curves for
hα6hβ4-nAChRs, for comparative analysis, we have
adopted the EC50 values for nicotine (7.1 μM) and ACh
Figure 8 Variations in nAChR hα6 subunit influence the ACh sensitivity of hα6hβ4*-nAChRs. (A) Representative traces are shown for
current responses from oocytes (voltage clamped at −70 mV) responding to the application of indicated concentrations of ACh (shown with
the duration of drug exposure as black bars above the traces) and expressing indicated nAChR (i.e., R1: hα6A184Dhβ4-nAChR, R2: hα6A184Dhβ4hβ3-
nAChR, R3: hα6hβ4hβ3-nAChR]. (B) Results averaged across experiments were used to produce concentration-response (CR) curves (ordinate-mean
normalized current ± SEM; abscissa - ligand concentration in log μM) for inward current responses to ACh as indicated for the nAChR expressed in
oocytes and voltage clamped at −70 mV. Current amplitudes are represented as a fraction of the peak inward current amplitude in response to the
most efficacious concentration of ACh. Leftward shifts in ACh CR curves for hα6R96Hhβ4hβ3-(●) [(B) (i)], hα6A184Dhβ4hβ3-(●) [(B) (ii)], hα6D199Yhβ4hβ3-
(●) [(B) (iii)], or hα6S233Chβ4hβ3-(●) [(B) (iv)] nAChR are evident relative to that of hα6hβ4hβ3-nAChR (○). Furthermore ACh curves for hα6A184Dhβ4-(■)
[(B) (ii)], hα6D199Yhβ4-(■) [(B) (iii)], or hα6S233Chβ4-(■) [(B) (iv)] nAChR are shifted leftward relative to those nAChR containing the same subunits but
in the additional presence of hβ3 subunits. See Table 3 for parameters of ACh action.
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tov et al. (2000). EC50 values generated for other variant
hα6hβ4*-nAChRs are provided in Tables 3 and Additional
file 1: Table S1. Results indicated that nicotine EC50 value
at hα6D199Yhβ4-nAChRs and ACh EC50 values at hα6
(A184D
or D199Y)hβ4-nAChRs are lower (~1.5-2.5 fold; p < 0.05)
than those of corresponding nAChRs additionally incorpor-
ating hβ3 subunits. Furthermore nicotine EC50 values athα6(A184D or S233C)hβ4hβ3-nAChRs and ACh EC50 values at
hα6(R96H, A184D, D199Y or S233C)hβ4hβ3-nAChRs are also
lower (~1.7-2.5 fold; p < 0.05) than those of hα6hβ4hβ3-
nAChRs. Hence nicotine or ACh sensitivity of hα6hβ4-
and/or hα6hβ4hβ3- nAChRs are marginally or significantly
increased as a result of Arg96His, Ala184Asp, Asp199Tyr
or Ser233Cys variations in hα6 subunit (Figure 8 and
Additional file 1: Figure S1, Tables 3 and Additional file 1:
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ation of nAChR hβ3 subunit into WT or variant hα6hβ4-
nAChR complexes result in marginally lower EC50 values
for nicotine or ACh.
Discussion
In discussion of our results we presume that empirical
changes in peak current levels and/or sensitivity of nAChRs
are indicative of successful incorporation of WT or mutant
β3 subunits into functional WT or variant hα6*-nAChRs.
However, in the absence of data for the effect of the varia-
tions in nAChR hα6 subunit on subunit biogenesis and
trafficking; receptor assembly and level of cell surface ex-
pression; ligand binding and channel open probability; etc.
we have relied on cell surface functional receptors to draw
inferences, conclusions and/or propose additional hypoth-
eses about functional expression of WT or variant hα6*-
nAChRs.
The inability to express functional hα6hβ2*-nAChRs
without use of gain-of-function hβ3 subunits (i.e.,
hβ3V9’S) confounds our ability to make inferences about
assembly of the WT subunits but it gives credence to
the idea that nAChR hβ3 subunits exert dominant nega-
tive effect on the function of α6β2*-nAChRs [25]. Alter-
natively, there possibly exists an undetectable level of
basal function for hα6hβ2hβ3-nAChRs that gets ampli-
fied upon substitution of hβ3V9’S subunits for hβ3 sub-
units. The lack of function for heterologously expressed
hα6hβ2- and hα6hβ2hβ3-nAChRs additionally could be
indicative of lack of presence of other nAChR subunits
(e.g., α3 or α4), chaperones or cellular components that
typically would facilitate assembly and functional expres-
sion of α6β2*-nAChRs in neurons or other cells
[26,27,29]. Nonetheless in this study we have success-
fully used hα6hβ2hβ3V9’S-nAChRs as a model to evalu-
ate the effect of variations in hα6 subunit on function of
hα6hβ2*-nAChRs. Our results are greatly enhanced by
the use of a codon optimized nAChR hβ2 subunit and
advantages of use of such codon-optimized nAChR sub-
units were demonstrated previously [27,28,37,38].
The current results and experimental approach indicate
that hβ3 subunits do not exert a dominant negative effect
on the function of hα6hβ4*-nAChRs [25-28]. Rather they
promote its functional expression as is shown here and
elsewhere [29]. It appears that hβ3 subunits need a consist-
ent basal level of expression of nAChR hα6 and hβ4 sub-
units, manifested as consistent functional expression of
hα6hβ4-nAChRs, for their integration and promotion of
functional expression of the resultant nAChRs. hα6hβ4-
nAChRs expressed using 1 ng or similar amount of cRNAs
for each subunit, typical for functional expression of many
other nAChR subtypes [36], are barely detected functionally
on cell surface. Further microinjection of hβ3 subunits in
similar amounts or in 20-fold excess of other α and βsubunits [25,26] seems not to affect the outcome but upon
substitution of hβ3V9’S subunits for hβ3 subunits there is
emergence of highly functional hα6hβ4hβ3V9’S-nAChRs.
Remember large excess of hβ3 subunits might be promot-
ing non-functional, dead-end intermediates [39] exacerbat-
ing the already poor expression of nAChR hα6 and hβ4
subunits or poor functional expression of hα6hβ4-nAChRs
leading to the notion that hβ3 subunits exert a dominant
negative effect on the function of hα6hβ4*-nAChRs. The
increased functionality of hα6hβ4hβ3-nAChRs relative to
hα6hβ4-nAChRs, rather than a null or decreased function-
ality [25], is analogous to studies using chimeric (α6/α3)
subunits (containing the N-terminal domain of the nAChR
α6 subunit substituting for that of the otherwise α3
subunit) instead of WT α6 subunits that shows a po-
tentiating effects of WT β3 subunit on function of (α6/α3)
(β2 or β4)*-nAChRs [29].
Consistent with the notion that oocytes expressing
hα6hβ4hβ3-nAChRs yield higher Imax than those ex-
pressing hα6hβ4-nAChRs, hα6(S43P, N46K, D92, R96H, E101K,
A112V, A184D, D199Y, N203T, I226T or S233C)hβ4hβ3- nAChRs
expressed in oocytes yield higher peak current responses
than those of their binary nAChR counterparts lacking
the hβ3 subunits. However, there is not a potentiation
effect on current responses upon incorporation of hβ3
subunits into presumed hα6(D57N, R87C, S156R or N171K)
hβ4- nAChR complexes. The lack of current responses
from oocytes expressing hα6(D57N, R87C, S156R or N171K)
hβ4hβ3-nAChRs, wherein hα6hβ4- and hα6hβ4hβ3-
nAChRs are functional, is probably not indicative of
exertion of dominant negative effect by nAChR hβ3
subunits. It appears that these variations in nAChR α6
subunit destroy the ability of participating subunits
to assemble into a typical functional nAChR. This is
because hα6(D57N, S156R or N171K)hβ4hβ3V9’S-nAChRs
display outward (positive) reversible current in responses
to nicotine or ACh defying the expectation that they
would display inward current responses like those
typically seen with hα6hβ4hβ3V9’S-nAChRs [26-28].
Also hα6(D57N, S156R or N171K)hβ4hβ3V9’S-nAChRs elicit
outward (positive) reversible current to atropine, a charac-
teristic that is also shared by spontaneously opening
hα6hβ4hβ3V9’S- or other β4β3*-nAChRs [26-28,36]
indicating that both nicotine and ACh are acting as
antagonists than as agonists at these nAChRs. The
antagonism of ACh or nicotine (and that of atropine)
appears to be due to the blockade of spontaneously
opening hα6(D57N, S156R, or N171K)hβ4hβ3V9’S-nAChRs.
Lack of consistent and reproducible current responses
from oocytes coexpressing hα6(D57N, R87C, S156R or N171K)
subunits with hβ2 and hβ3V9’S subunits; or with hβ4 sub-
units probably indicate that these variations, respectively,
presumably in the N-terminal α-helix, strand β2, strand
β6 and cysteine-loop disrupt assembly of the subunits into
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encountered with hα6(D57N, R87C, S156R or N171K)hβ4hβ3-
nAChRs. The Asn171 residue in hα6 subunit, mutated to
Lys (K), is a potential target for N-glycosylation. Potential
de-glycosylation of the nAChR hα6 subunit as a result of
the Asn171Lys variation could affect stability and traffick-
ing of hα6(N171K)hβ2hβ3V9’S-, hα6(N171K)hβ4-, hα6
(N171K)hβ4hβ3- or hα6(N171K)hβ4hβ3V9’S-nAChRs to
the cell surface [40,41]. The outward current responses of
hα6N171Khβ4hβ3V9’S-nAChR to ACh or nicotine, in con-
trast to an expected inward current, probably corroborate
this point. Also the Asn171Lys variation in hα6 subunit
could disrupt the essential role of the cys-loop in coupling
agonist (e.g., nicotine) binding to channel gating (opening)
in hα6hβ2*-, hα6hβ4- or hα6hβ4hβ3- nAChRs. Note that
Asp57, Arg87, Ser156 and Asn171 residues of hα6 subunit
are strongly conserved in nAChR subunits from various
organisms indicating that a variation in these residues
could not be tolerated without negative consequences on
the structure-function relationship of hα6*-nAChRs.
Additionally it appears elimination of a positively charged
residue at AA position 87 (Arg87Cys) or introduction of a
positively charged residue at position 171 (Asn171Lys) is
having negative functional consequences.
For oocytes expressing hα6(S43P, N46K or D92E)hβ2hβ3V9’S-,
hα6D92Ehβ4- or hα6D92Ehβ4hβ3-nAChRs to display com-
promised or reduced current responses could be due to
decreased cell surface functional expression of these recep-
tors. Additionally it could be due to change in inherent
structure of the receptor molecules because of the indi-
cated AA variations. It appears that the Asp92 residue,
strongly conserved across various nAChR subunits located
in loop D (β2-β3 loop) in the complementary face of the
hα6 subunit, upon mutation to a glutamate (that results in
an increase in AA side chain length) is having a negative
effect on the subunit assembly of α6β2β3V9’S-, α6β4-, or
α6β4β3- nAChRs possibly by affecting the subunit inter-
action at the positive (+) face of the β2 or β4 subunit and
negative (−) face of the α6 subunit [i.e., β2 or β4 (+):
(−)α6]; and/or at the positive (+) face of the β3 or
β3V9’S subunit and the negative (−) face of the α6
subunit [i.e., β3 or β3V9’S(+):(−)α6] [Figure 2(C), (D)
and (E)]. The reduction in current responses of
hα6hβ2hβ3V9’S-nAChRs but not those of hα6hβ4- or
hα6hβ4hβ3-nAChRs as a result of Ser43Pro variation in
hα6 subunit could be due to a subtype specific effect of
the variation. Similarly a reduction in current responses of
hα6hβ2hβ3V9’S-nAChRs; no change in current responses
of hα6hβ4hβ3-nAChRs; and an increase in current
responses of hα6hβ4-nAChRs as a result of Asn46Lys
variation in hα6 subunit could be a subtype specific effect
of the variation. This in turn could be attributed to the
introduction of a positively charged residue (i.e., Lys) at
AA position 46 in hα6 subunit.Variations in nAChR hα6 subunit that occur at residue
101 (Glu101Lys: β2-β3 loop/loop D), 112 (Ala112Val:
loop A), 184 (Ala184Asp: loop B), 203 (Asn203Thr: loop F)
or 226 (Ile226Thr: loop C) do not affect the peak current
responses of hα6hβ2hβ3V9’S- or hα6hβ4hβ3-nAChRs, an
indication that natural AA substitutions at these positions
do not grossly affect the assembly, cell surface expression
and/or structure-function relationship of these nAChRs.
However, variations in loops A (Ala112Val), B (Ala184Asp)
or C (Ile226Thr) in hα6 subunit substantially increases
current responses from minimally functional hα6hβ4-
nAChRs signifying the emerging notion that N-terminal
loop residues are important in the assembly and functional
expression of hα6*-nAChRs [26-28]. Also it is of signifi-
cance that some of these variations in various loop residues
are innocuous or beneficial for the functional expression
of hα6hβ2hβ3V9’S-, hα6hβ4- or hα6hβ4hβ3-nAChRs an
indication that these substitutions are tolerated in regions
that are crucial in ligand binding and/or subunit assembly.
Coincidentally hα6 subunits have non-conserved AAs at
position 101 (Glu), 112 (Ala), 184 (Ala) or 226 (Ile); and a
weakly conserved AA at position 203 (Asn) in an align-
ment analyses of human nAChR α subunits (see Figure 1).
A weak or nonconserved AA residue probably indicates,
but not necessarily always, a tolerance for these substitu-
tions. However, such a broader interpretation becomes
difficult to generalize as hα6 subunit seems to have
strongly conserved AAs at positions 101 (Glu), 112 (Ala),
184 (Ala) and 226 (Ile) and a weakly conserved AA at pos-
ition 203 (Asn) in an alignment analysis of α6 subunits
from a limited number of other species.
Variations that occur in the nAChR hα6 subunit at
AA residues 96 (Arg96His: β2-β3 loop/loop D), 199
(Asp199Tyr: loop F) or 233 (Ser233Cys: strand β10)
increases the peak current responses from oocytes
expressing hα6hβ2hβ3V9’S-nAChRs. However, these
variations except Asp199Tyr do not have any effect on
the peak current responses of hα6hβ4- or hα6hβ4hβ3-
nAChRs expressed in oocytes again demonstrating a sub-
type specific effect of these variations in β2-β3 loop/loop
D, loop F or β10-strand of hα6 subunit. It appears that the
Arg96 or Asp199 residue located in the complementary face
of the hα6 subunit is exerting a positive effect on the
subunit assembly of α6β2β3V9’S- and α6β4-nAChRs
possibly by affecting the subunit interaction at the positive
(+) face of the β2 or β4 subunit and negative (−) face of
the α6 subunit [i.e., β2 or β4 (+):(−)α6] ; and/or at the
positive (+) face of the β3 or β3V9’S subunit and the nega-
tive (−) face of the α6 subunit [i.e., β3 or β3V9’S(+):(−)α6]
[Figure 2(C), (D) and (E)]. These results are similar to pre-
viously described reports that AA residue (e.g., Asn143:
loop E) located in the negative face of the hα6 subunit
influence the functional expression of hα6hβ2hβ3V9’S-
nAChRs [26].
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parisons of EC50 values among WT and variant hα6hβ4-
nAChRs remained incomplete. However, it is reported
[29] that ACh (18 ± 5 μM) or nicotine (7.1 ± 2.6 μM)
EC50 values at hα6hβ4-nAChRs are marginally lower
than those of respective hα6hβ4hβ3-nAChRs (ACh EC50:
33 ± 8 μM and nicotine EC50:10 ± 3 μM). Our results
indicate that this directionality in change in potency is
preserved for hα6(A184D, D199Y or S233C)hβ4- nAChRs indi-
cating that EC50 values at hα6
(A184D, D199Y or S233C)hβ4-
nAChRs is lower than those containing the same subunits
but also additionally containing nAChR hβ3 subunits. But
note that the increase in agonist sensitivity of nAChRs as
a result of the variations in loop B (Ala184Asp), loop F
(Asp199Tyr) and β strand 10 (Ser233Cys) (which connect
to the trans-membrane domain I) in hα6 subunit are
nominal implying that there could be subtle changes in
receptor structures.
In the final analyses it is incumbent upon us to know
the significance, if any, of these variations in hα6 subunit
in the etiology of nicotine dependence and/or other
hα6*-nAChR involved diseases. We would not know
them until currently available tools, statistical or bio-
technological, becomes mainstream. Specifically analyses
of rare variations (i.e., Asp57Asn, Arg87Cys, Ser156Arg
or Asn171Lys) in nAChR hα6 subunit that compromise
the function of hα6*-nAChRs would be of prime interest
in epidemiological or in vivo studies. Nonetheless individ-
uals displaying altered hα6*-nAChR pharmacology as a re-
sult of rare variation in nAChR hα6 subunit are expected
to exhibit differential responses to smoked nicotine.
Conclusions
Our results presented here are in general agreement
with the accumulated evidences that changes/mutations
in loop residues and other structural residues could
affect cell surface expression, assembly, structure and/or
function of various nAChRs. Specifically N-terminal α-
helix (Asp57); complementary face/inner β-fold (Arg87 or
Asp92) and principal face/outer β-fold (Ser156 or Asn171)
residues in hα6 subunit are crucial for functional expres-
sion of hα6hβ2*-, hα6hβ4- and hα6hβ4hβ3-nAChRs and
natural variations in them (i.e., Asp57Asn, Arg87Cys,
Asp92Glu, Ser156Arg or Asn171Lys) compromises their
function. Additionally Ser43 or Asn46 (N-terminal α-helix)
residues in hα6 subunit are important for functional
expression of hα6hβ2*-nAChRs and natural variations
in them (i.e., Ser43Pro or Asn46Lys) compromise its
function. However, natural variations indicate Arg96
(β2-β3 loop/loop D), Asp199 (loop F) or Ser233 (β10-
strand) residues in hα6 subunit could be taken advantage
for promoting functional expression of hα6hβ2*-nAChRs.
Similarly residues in N-terminal α-helix (Asn46), loop A
(Ala112), loop B (Ala184), loop F (Asp199) or loop C (Ile226)could be substituted with their respective natural varia-
tions (i.e., Asn46Lys, Glu101Lys, Ala112Val, Ala184Asp,
Asp199Tyr or Ile226Thr) for increased functional expres-
sion of poorly functional/expressed hα6hβ4-nAChRs.
Thus, by studying natural variations in nAChR hα6 sub-
unit, we have mapped AA residues in nAChR hα6 subunit
important for cell surface functional expression of various
subtypes of hα6*-nAChRs. These novel sites in nAChR
hα6 subunit could be of promising use for creation of
functional cell lines that could be helpful for drug screen-
ing; and development of new drug candidates selective for
hα6*-nAChRs. This is of increasing importance given the
potentially important roles for α6*-nAChRs in movement




Human nAChR α (α1- α7, α9, α10) subunits or nAChR
α6 subunits from various organisms were aligned using
ClustalW and then edited for the purposes of presenta-
tion (Figure 1). A homology model of the human nAChR
α6 subunit modeled on the 3-D coordinates of the
muscle nAChR α subunit of Torpedo marmorata (PDB:
2BG9.A) [2] was retrieved using SWISS-MODEL [45]
protein modeling server; and subsequently was rendered
using UCSF Chimera (http://www.cgl.ucsf.edu/chimera/),
a program for interactive visualization and analysis of
molecular structures (Figure 2).
Chemicals
All chemicals used in electrophysiology were obtained
from Sigma Chemical Co. (St. Louis, MO, USA) except
that L-nicotine was obtained from Arcos Organics (New
Jersey, USA). Fresh agonist (acetylcholine or nicotine)
and antagonist (atropine) stock solutions were made
daily or diluted from frozen stock in Ringer's solution
(OR2) which consisted of (in mM) 92.5 NaCl, 2.5 KCl, 1
CaCl2, 1 MgCl2, and 5 HEPES; pH 7.5.
Subcloning, mutagenesis and in vitro transcription of
nAChR subunits
Wild type nAChR subunits (hα6, hβ2 and hβ3) and
gain-of-function nAChR hβ3 subunits (i.e., hβ3V9’S,
where V9’S indicated valine-to-serine mutation in the so
called 9’ position of the channel lining second trans-
membrane domain) were subcloned previously [26-28].
A synthetic nAChR hβ2 subunit with codon sequences
optimized (GenBank Accession Number JN565027) for
better heterologous expression was made (Invitrogen/
GENEART, Burlingame, CA) and subcloned into the pCI
vector (Promega, San Luis Obispo, CA) [26,28,38]. Missense
mutations (i.e., Ser43Pro, Asn46lys, Asp57Asn, Arg87Cys,
Asp92Glu, Arg96His, Glu101Lys, Ala112Val, Ser156Arg,
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and Ser233Cys) in the nAChR hα6 subunit were introduced
in the pGEMHE (oocyte expression vector) background
using HPLC purified oligonucleotides listed in Table 2. Ac-
curacy of all mutant subunits were confirmed by sequen-
cing referenced to nucleotide/protein sequences available
in GenBank. Full length capped mRNA (i.e., cRNA) was
transcribed from linearized plasmids using mMESSAGE
mMACHINE® T7 Kit (Invitrogen/Ambion Inc., Carlsbad,
CA). Integrity and quality of the cRNA was checked by
electrophoresis and UV-spectroscopy.
Preparation of cRNA mixture for Xenopus oocyte
microinjection
We planned to introduce identical amounts of cRNA,
presumably producing equal amounts of each subunit
protein, into oocytes largely due to lack of information
about the levels of mRNA for each subunits that com-
pose α6*-nAChRs in neurons or other cells. Concen-
trations of cRNAs for each nAChR α and β subunits
(WT, mutant or variant) were adjusted to 500 ng μL−1.
We provisionally assumed that hα6 or its variants in
association with hβ2 or hβ4 subunits would form com-
plexes having 2:3 and/or 3:2 ratios of the indicated sub-
units and that oocytes also injected with WT or mutant
form of β3 subunits (i.e., β3V9’S) would express nAChR
with 2:2:1 ratios of α:β:(β3 or β3V9’S) subunits. For expres-
sion of binary nAChRs (i.e., two subunit containing
nAChRs; α + β but not β3) cRNA mixtures were prepared
by mixing 1 μL of cRNA for each subunit and an
additional μL of RNAse free water (i.e., total volume
3 μL). Similarly for expression of ternary nAChRs [i.e.,
three subunit containing nAChRs; (α + β) + (β3 or β3V9’S)]
cRNA mixtures were prepared by mixing 1 μL of cRNA
for each subunit. Several preparations of each mixture
were prepared and stored at −80°C until further use. Injec-
tion of 138 nL of cRNA, out of 3 μL cRNA mixtures, into
each oocyte would deliver ~23 ng of cRNA for each sub-
unit whether binary or ternary nAChRs are expressed.
Oocyte preparation and cRNA microinjection
All Xenopus laevis (Nasco, Fort Atkinson, WI, USA)
procedures were conducted in accordance with the
guidelines of the National Institutes of Health (NIH) for
the proper use of laboratory animals and approved by
the Institutional Animal Care and Use Committee (IACU)
of University of Virginia. Female Xenopus laevis (Nasco,
Fort Atkinson, WI) were anesthetized using 0.2% tricaine
methanesulfonate (MS-222) (Nasco, Fort Atkinson, WI).
Ovarian lobes were surgically removed from the frogs and
placed in an incubation solution that consisted of (in mM)
82.5 NaCl, 2.5 KCl, 1 MgCl2, 1 CaCl2, 1 Na2HPO4, 0.6
theophylline, 2.5 sodium pyruvate, 5 HEPES, 50 mg/ml
gentamycin, 50 U/ml penicillin, and 50 μg/ml streptomycin;pH 7.5. The lobes were cut into small pieces and digested
with Liberase™ (research grade, medium Thermolysin
concentration; Roche Applied Science, Indianapolis, IN)
with constant stirring at room temperature for 1.5-2
hours. The dispersed oocytes were thoroughly rinsed with
incubation solution. Stage VI oocytes were selected
and incubated at 16°C before injection. Micropipettes
used for injection were pulled from borosilicate glass
(Drummond Scientific, Broomall, PA) using a Sutter
P1000 horizontal puller, and the tips were broken
with forceps to ~40 μm in diameter. cRNA was drawn up
into the micropipette and injected into oocytes using a
Nanoject microinjection system (Drummond Scientific) at
a total volume of 138 nL.Oocyte electrophysiology
Two to 5 days after injection, oocytes were placed in a
small-volume chamber and continuously perfused with
OR2. The chamber was grounded through an agarose
bridge. The oocytes were voltage-clamped at −70 mV
(unless otherwise noted) to measure agonist or antagon-
ist induced currents using Axoclamp 900A and pClamp
10.2 software (Molecular Devices, Sunnyvale, CA). The
current signal was low-pass filtered at 10 Hz with the
built-in low-pass Bessel filter in the Axoclamp 900A
and digitized at 20 Hz with Axon Digidata1440A and
pClamp10. Electrodes contained 3 M KCl and had a
resistance of 1–2 MΩ. Drugs (agonists and antagonists)
were prepared daily in OR2. Drug was applied using a Val-
velink 8.2 perfusion system (Automate scientific, Berkeley,
CA). One micromolar (1 μM) atropine was always co-
applied for acetylcholine (ACh)-based recordings to elim-
inate muscarinic AChR (mAChR) responses. nAChR hα6
constructs were tested individually or in batches as they
became available to get an approximate idea about their
effect on the function of hα6*-nAChRs. Then for the
purpose of comparison electrophysiological recordings
were performed in a given day in a given batch of oocytes
following the same order of injections. Hence data points
in a figure panel were obtained under almost similar
experimental conditions. All hβ4*-nAChR recordings were
done in similar conditions to facilitate comparisons
between hα6hβ4- and hα6hβ4hβ3-nAChRs. All electro-
physiological measurements were conducted or checked
in at least two batches of oocytes.Experimental controls
Injection of water or empty vector or of cRNA corre-
sponding to one subunit alone or pairwise combinations
of β3 or β3V9’S subunits with either an α or β2 or β4 sub-
unit did not result in the expression of functional nAChR.
Current responses from these oocytes to 100 μM nicotine
were less than 5–10 nA (data not shown).
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Raw data was collected and processed in part using
pClamp 10.2 (Molecular Devices, Sunnyvale, CA), Origin
7.5 (OriginLab Corporation, Northampton, MA) and a
spreadsheet (Excel; Microsoft, Bellevue, WA). Peak current
amplitudes (Imax) are reported as mean ± SEM (for results
from at least three oocytes, i.e., n = 3). Concentration-
response (CR) relationships, in which mean peak current
amplitudes at specified ligand concentrations were fit to
the Hill equation or its variants using Prism 4 (GraphPad
Software, San Diego, CA), were constructed to assess true
Imax (mean current amplitudes in response to the most
efficacious concentration of an agonist) and EC50 (con-
centration for half-maximal activation) values. The F-test
(p < 0.05 to define statistical significance) was used to
compare the best-fit values of log molar EC50 values
across specific nAChR subunit combinations. EC50 values
with non-overlapping 95% confidence intervals (CI) are
deemed to be statistically significant (p < 0.05).
There are limitations in the ability to compare peak
current responses of nAChRs, even though we injected
similar amounts of cRNAs for 1:1 or 1:1:1 coexpressions,
as described previously [27,28]. This is because expression
levels assessed as peak current amplitudes are affected by
batch-to-batch variation in oocytes, time between cRNA
injection and recording, and subunit combination-specific
parameters, such as open probability (influenced by gating
rate constants, rates and extents of desensitization), single
channel conductance, assembly efficiency, and effi-
ciency of receptor trafficking to the cell surface [46].
We made no attempt to measure or control for subunit
combination-specific effects, but whenever preliminary
studies revealed possible differences in peak current am-
plitudes, findings were further confirmed across different
subunit combinations using the same batch of oocytes
and the same time between cRNA injection and recording.
However, when we make statements about results com-
paring ligand potencies and peak current amplitudes
across subunit combinations, we do so for studies done
under the same or very similar conditions, and the obser-
vations are clear, statistically significant, and in agreement
whether for pooled data or for results from smaller
sets of studies. The Imax values of the WT and variant
hα6*-nAChRs were compared using Student’s t-test
(two-tailed. *, p < 0.05; **, p < 0.01; and ***, p < 0.001)
or ANOVA (followed by Tukey’s or Dunnett’s mul-
tiple comparisons test; *, p < 0.05; **, p < 0.01; and ***,
p < 0.001).
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